Showing 3191-3200 of 5773 results for "".
- Rayner's RayOne EMV Receives Health Canada Approvalhttps://modernod.com/news/rayners-rayone-emv-receives-health-canada-approval/2482076/Rayner announced the approval of RayOne EMV by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration to slightly extend the depth of focus, according to Rayner [1].
- DigitalOptometrics Launches DOT Translation Servicehttps://modernod.com/news/digitaloptometrics-launches-dot-translation-service/2482073/DigitalOptometrics announced the launch of “DOT” (DigitalOptometrics Translate), a new translation service that aims to improve patient care. “DOT” is a real-time translation technology that breaks language barriers, allowing eye care professionals to commun
- Sydnexis Appoints Erin Horn as Vice President, Head of Market Accesshttps://modernod.com/news/sydnexis-names-erin-horn-as-vice-president-head-of-market-access/2482071/Sydnexis has announced the appointment of Erin Horn as Vice President, Head of Market Access. Ms. Horn will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, Ms. Horn has a track record of commercial success
- iuvo BioScience Acquires Promedica International to Expand Ophthalmic Clinical CRO Serviceshttps://modernod.com/news/iuvo-bioscience-acquires-promedica-international-to-expand-ophthalmic-clinical-cro-services/2482070/Partner Research Organization iuvo BioScience announced it has acquired Promedica International (PMI), an ophthalmology-focused clinical CRO. Financial terms of the deal were not disclosed. The companies say the combined organization will support all aspects of opht
- Lineage's RG6501 (OpRegen) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Meetinghttps://modernod.com/news/lineages-rg6501-opregen-phase-12a-results-will-be-featured-at-2024-angiogenesis-meeting/2482068/Lineage Cell Therapeutics announced that results showing retinal structure improvements with RG6501 (OpRegen) from a phase 1/2a clinical study (ClinicalTrials.gov Identifier:
- LumiThera Initiates EUROLIGHT Registry Study to Evaluate Long-Term Benefits of PBM Using the Valeda for Dry AMDhttps://modernod.com/news/lumithera-initiates-eurolight-registry-study-to-evaluate-long-term-benefits-of-pbm-using-the-valeda-light-delivery-system-for-dry-amd/2482067/LumiThera announced the initiation of the largest PBM trial ever conducted in patients with dry age-related macular degeneration (AMD). A global registry data collection from patients treated with PBM using the Valeda Light Delivery System has been established with Dendrite Clinica
- Decision on the Adoption of a Sale Plan for Pixium Vision Postponedhttps://modernod.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.</
- Rayner Acquires This AG, Maker of Sophi Phaco Machineshttps://modernod.com/news/rayner-acquires-this-ag-maker-of-sophi-phaco-machines/2482064/Rayner announced that it has entered into a definitive agreement to acquire Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines. Financial terms of the deal were not disclosed. The acquisition marks a new chapter for R
- Nidek and Orbis International Partner to Scale Up Artificial Intelligence Eye Screenings in Vietnamhttps://modernod.com/news/nidek-and-orbis-international-partner-to-scale-up-artificial-intelligence-eye-screenings-in-vietnam/2482060/Nidek announced a donation to Orbis International to support Orbis’s artificial intelligence-based screening services in Vietnam. The donation of six specialized fundus cameras, which take images of the retina, will support the scale up of Orbis’ AI-based diabetic retinopathy scr
- Aviceda Enrolls First Patient in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of DMEhttps://modernod.com/news/aviceda-enrolls-first-patient-in-phase-2-glyco-clinical-trial-evaluating-avd-104-for-the-treatment-of-dme/2482058/Aviceda Therapeutics announced that it has enrolled the first patient in the GLYCO phase 2 US clinical trial evaluating its lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammati